In Part 6 of Elizabeth Holmes' sworn SEC deposition regarding Theranos, questioning focuses intently on investor projections, internal communications with Sunny Balwani, and the company's tumultuous interactions with the FDA. The testimony begins with an examination of the financial projections provided to Rupert Murdoch, scrutinizing claims that revenue forecasts were based on already-signed contracts. Investigators then review internal text messages between Holmes and Sunny Balwani regarding financial models. Finally, the deposition shifts to a deep dive into Theranos’s regulatory status with the FDA—probing whether the proprietary Nanotainer and testing systems complied with Laboratory Developed Test (LDT) guidelines, the validity of capillary versus venous blood data, and warnings from regulators about significant test inaccuracy and bias. Listen To Hidden Killers Podcast ANYWHERE! Listen Here: https://linktr.ee/hiddenkillers Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.